In a significant portfolio shift, Lee Ainslie's Maverick Capital fully liquidated its position in Abbott Laboratories during the second quarter of 2026. The sale involved all 1.76 million shares, which were valued at approximately $180.5 million at the end of the first quarter. This holding had represented over 2% of the fund's reported portfolio.
This disclosure comes from a quarterly 13F filing with the SEC, which is released with a delay and reflects the fund's holdings as of June 30, 2026. The move is particularly noteworthy as Maverick had just initiated this large stake in Abbott Labs in the first quarter of the year. The firm has not publicly commented on its specific rationale for this quick reversal and sale.